Edwin Coe advised Onzima Ventures Plc on the acquisition of the remaining 51% of the issued shares of N4 Pharma Limited which it did not already own. The transaction constituted a Reverse Takeover and entailed the re-admission of the enlarged entity to AIM.

The company also raised £1.5 million via a share placing which, it said, will be used to fund the development of additional patent applications for reformulations of a wide range of generic drugs, to undertake clinical trials for N4 Pharma’s reformulation of sildenafil and for working capital purposes.

The Edwin Coe team was led by Head of Corporate & Commercial Russel Shear, who commented: “We are delighted to have assisted Onzima Ventures on this acquisition and its re-admission to AIM as N4 Pharma.”

About Edwin Coe

Edwin Coe is a London-based full service law firm with international reach. Since 1913, we have offered a comprehensive range of integrated legal services to meet the needs of individuals, organisations and businesses based throughout the UK and internationally. Our industry-leading experts provide our clients with highly personal and responsive advice, balancing profit and purpose, to help achieve their personal and business goals.

With 39 Partners, we are ranked 115 in the current edition of The Lawyer’s ‘UK 200’ law firms and are recommended in all the major legal directories. We are proud to be B Corp™ certified, part of a global community of businesses working to redefine success in business, and create a more inclusive and sustainable economy.

Latest News & Events See All

Share by: